Document and Entity Information Statement [Table] Statement [Line Items] Statement Document Type Document Quarterly Report Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Central Index Key Amendment Flag CONDENSED CONSOLIDATED BALANCE SHEETS Class of Stock [Axis] Class of Stock [Domain] This member stands for series D convertible preferred stock. Series D Convertible Preferred Stock [Member] Series D Convertible Preferred Stock Assets [Abstract] ASSETS Assets, Current [Abstract] CURRENT ASSETS: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property, plant & equipment, net Operating Lease, Right-of-Use Asset Operating lease right-of-use asset Other Assets, Noncurrent Other long-term assets Assets TOTAL ASSETS Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] CURRENT LIABILITIES: Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued liabilities Derivative Liability, Current Warrant liability Operating Lease, Liability, Current Lease liability, current Liabilities, Current Total current liabilities Operating Lease, Liability, Noncurrent Lease liability, net of current portion Liabilities TOTAL LIABILITIES Commitments and Contingencies. COMMITMENTS AND CONTINGENCIES (Note 7) Temporary Equity [Abstract] MEZZANINE EQUITY: Temporary Equity, Carrying Amount, Attributable to Parent Balance ending Series D preferred stock Balance beginning Series D preferred stock Series D preferred stock, 111.11 shares authorized, 0.00 and 111.11 issued and outstanding as of June 30, 2026 and December 31, 2025, respectively Stockholders' Equity Attributable to Parent [Abstract] STOCKHOLDERS' EQUITY: Preferred Stock, Value, Issued Series E-2 preferred stock, 1,225 shares authorized; 0.00 and 35.60 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively Common Stock, Value, Issued Common stock, $0.00001 par value; 170,000,000 shares authorized; 8,252,108 and 4,240,129 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders' Equity Attributable to Parent Balance ending Balance beginning Total stockholders' equity Liabilities and Equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Represents the information pertaining to Series E-2 preferred stock. Series E-2 Preferred Stock [Member] Series E-2 Preferred Stock Temporary Equity, Shares Authorized Temporary equity, preferred stock, shares authorized Temporary Equity, Shares Issued Temporary equity, preferred stock, shares issued Temporary Equity, Shares Outstanding Balance ending Series D preferred stock (in shares) Balance beginning Series D preferred stock (in shares) Temporary equity, preferred stock, shares outstanding Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, share issued Preferred Stock, Shares Outstanding Preferred stock, share outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common stock par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Operating Costs and Expenses [Abstract] OPERATING EXPENSES: Research and Development Expense Research and development General and Administrative Expense General and administrative Costs and Expenses Total operating expenses Operating Income (Loss) LOSS FROM OPERATIONS Nonoperating Income (Expense) [Abstract] OTHER INCOME (EXPENSE): Fair Value Adjustment of Warrants Gain (loss) on valuation of warrants Change in fair value of warrants Interest Income (Expense), Nonoperating, Net Interest income Nonoperating Income (Expense) Total other income (expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest LOSS BEFORE INCOME TAXES Net loss Segment and consolidated net loss NET LOSS Net loss Earnings Per Share, Basic NET LOSS PER SHARE - BASIC (In dollars per share) Earnings Per Share, Diluted NET LOSS PER SHARE - DILUTED (In dollars per share) Weighted Average Number of Shares Outstanding, Basic WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING - BASIC (In shares) Weighted Average Number of Shares Outstanding, Diluted WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING - DILUTED (In shares) CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Represents the information pertaining to pre-funded warrants. Pre-funded warrants Equity Components [Axis] Equity Component [Domain] Preferred Stock [Member] Preferred Stock Common Stock [Member] Common Stock Additional Paid-In Capital [Member] Additional Paid-In Capital Retained Earnings [Member] Accumulated Deficit Series D Preferred Stock [Member] Series D preferred stock Represents the information pertaining to Series E-4 preferred stock. Series E-4 Preferred Stock [Member] Series E-4 preferred stock Shares, Issued Balance ending (in shares) Balance beginning (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation Value of new stock and warrants issued during the period. Stock Issued During Period, Value, Stock And Warrants Issuance of common stock and pre-funded warrants, net of issuance costs Number of new stock and warrants issued during the period. Stock Issued During Period, Shares, Stock And Warrants Issuance of common stock and pre-funded warrants, net of issuance costs (in shares) Stock Issued During Period, Value, Conversion of Convertible Securities Conversion of preferred stock into common stock Stock Issued During Period, Shares, Conversion of Convertible Securities Conversion of preferred shares into common shares (in shares) Conversion of preferred stock into common stock (in shares) Amount of exercise of warrants into preferred shares. Exercise of Warrants Into Preferred Shares, Value Exercise of warrants for preferred stock, net of issuance costs (Note 2) Number of shares issued at exercise of warrants into preferred shares. Exercise of Warrants Into Preferred Shares, Shares Exercise of warrants for preferred stock, net of issuance costs (Note 2) (in shares) Exercise of warrants into preferred shares (in shares) CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to cash used in operating activities: Amount expended on depreciation and amortization of assets Depreciation and Amortization of Assets Depreciation and amortization Share-based Compensation Stock-based compensation expense Total stock-based compensation Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. Increase Decrease In Operating Lease Right Of Use Asset Change in operating lease right-of-use asset Increase (Decrease) in Operating Capital [Abstract] Changes in: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Operating Lease Liability Lease liability Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities Net Cash Provided by (Used in) Operating Activities Cash flows from operations Cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Payments to Acquire Property, Plant, and Equipment Purchases of property, plant & equipment Net Cash Provided by (Used in) Investing Activities Cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: The cash inflow associated with the amount received from holders exercising their stock warrants, net of cost paid. Proceeds From Warrant Exercises, Net Of Costs Net proceeds from warrant exercises Proceeds from exercise of warrants, net of issuance costs (Note 2) The net cash inflow from the additional capital contribution to the entity and rights to purchase common shares at predetermined price after the issuance costs. Proceeds From Issuance Of Common Stock And Warrants, Net Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs (Note 2) Net Cash Provided by (Used in) Financing Activities Cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents CASH AND CASH EQUIVALENTS AT END OF PERIOD CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD Supplemental Cash Flow Information [Abstract] SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Represents the settlement of warrants to equity in non cash disclosure of cash flow information. Settlement of Warrants to Equity Settlement of warrants to equity Conversion of Stock, Amount Converted Conversion of preferred stock to common stock Represents the value of warrants issued to placement agent in non cash disclosure of cash flow information. Value of warrants issued to placement agent Value of warrants issued to placement agent Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right of use asset obtained in exchange for operating lease liability NATURE OF BUSINESS AND ORGANIZATION Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] NATURE OF BUSINESS AND ORGANIZATION STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] STOCKHOLDERS' EQUITY FAIR VALUE Fair Value Disclosures [Text Block] FAIR VALUE STOCK-BASED COMPENSATION Disclosure of Compensation Related Costs, Share-based Payments [Text Block] STOCK-BASED COMPENSATION INCOME TAXES Income Tax Disclosure [Text Block] INCOME TAXES NET LOSS PER SHARE Earnings Per Share [Text Block] NET LOSS PER SHARE COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES LEASES Lessee, Operating Leases [Text Block] LEASES OPERATING SEGMENT Segment Reporting Disclosure [Text Block] OPERATING SEGMENT SUBSEQUENT EVENTS Subsequent Events [Text Block] SUBSEQUENT EVENTS Disclosure of accounting policy for going concern. Going Concern [Policy Text Block] Going Concern Consolidation, Policy [Policy Text Block] Principles of Consolidation Use of Estimates, Policy [Policy Text Block] Use of Estimates Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Property, Plant and Equipment, Policy [Policy Text Block] Property, Plant & Equipment Disclosure of accounting policy for right of use assets and lease liability. Right Of Use Assets And Lease Liability Policy [Policy Text Block] Right-of-Use Asset and Lease Liabilities Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Stock-Based Compensation Research and Development Expense, Policy [Policy Text Block] Research and Development Income Tax, Policy [Policy Text Block] Income Taxes Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Derivatives, Policy [Policy Text Block] Warrants Stockholders' Equity, Policy [Policy Text Block] Preferred Stock Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk Government Assistance [Policy Text Block] Government Assistance New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Pronouncements Not Yet Adopted Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Summary of outstanding warrants to purchase common stock Fair Value Measurements, Recurring and Nonrecurring [Table] Represents information pertaining to July 2024 warrants. July 2024 Warrants [Member] July 2024 Warrants Represents information pertaining to September 2023 warrants. September 2023 Warrants [Member] September 2023 Warrants This member stands for 2022 common warrants. Two Thousand Twenty Two Common Warrants [Member] 2022 Common Warrants October 2022 Warrants Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] FAIR VALUE Fair Value, Assets Measured on Recurring Basis [Table Text Block] Schedule of financial instruments measured at fair value on a recurring basis Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block] Schedule of modified option pricing assumptions and assumptions used upon issuance Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of changes in the fair market value of the warrants Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] Summary of the expense for stock-based compensation related to stock option grants Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of dilutive securities have been excluded from the computation of diluted net loss per share Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of the Company's undiscounted payments for its short-term leases and operating lease liabilities Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Schedule of financial data for the one reportable segment Disclosure information about Nature of Business and Organization. Nature of Business and Organization [Table] Range [Axis] Range [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Leasehold Improvements [Member] Leasehold improvements Government Assistance, Type [Axis] Government Assistance, Type [Domain] Represents the information pertaining to cancer treatment research award through the National Cancer Institute (NCI). Cancer Treatment Research Award Through National Cancer Institute [Member] Cancer treatment research award through the National Cancer Institute (NCI) Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Nature of Business and Organization [ Line Item] NATURE OF BUSINESS AND ORGANIZATION Carrying amount as of the balance sheet date of cash and cash equivalents with respect to unrestricted balances. Unrestricted Cash and Cash Equivalents Unrestricted cash and cash equivalents Aggregate upfront amount of shares reserved for future issuance. Stock, Capital Reserved for Future Issuance, Upfront Additional securities purchase agreement, upfront Maximum milestone based amount of shares reserved for future issuance. Stock, Maximum Capital Reserved for Future Issuance, Milestone Based Additional securities purchase agreement, milestone based Number of Reportable Segments Number of reportable segments Tangible Asset Impairment Charges Fixed asset impairment charges Unrecognized Tax Benefits, Period Increase (Decrease) Cash, Uninsured Amount Uninsured cash balances Property, Plant and Equipment, Useful Life Property and equipment useful lives Government Assistance, Amount Grant received Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration] Government Assistance, Transaction Duration Period over which cancer treatment research award was received. Amount of proceeds from research and development. Proceeds From Research And Development Reduction in research and development Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Share-based compensation expiration period Class of Warrant or Right [Table] This member stands for common stock warrant. Common Stock Warrant [Member] Common warrant This member stands for Prefunded Warrant. Prefunded Warrant [Member] Prefunded Warrant Represents information pertaining to warrants issued by the company on June 5, 2020, October 25, 2022 and July 21, 2024, collectively referred as existing warrants. Existing Warrants [Member] Existing Warrant Represents information pertaining to warrants inducement by the company October 2025. Two Thousand Twenty Five October Warrants [Member] October 2025 Warrant Inducement Represents information pertaining to Tranche A warrants. Tranche A Warrants [Member] Tranche A Warrants Represents information pertaining to 2026 May Tranche C Common Warrants. Two Thousand Twenty Six May Tranche C Common Warrants [Member] 2026 May Tranche C Common Warrants Represents information Pertaining to 2026 May Placement Agent Warrants. Two Thousand Twenty Six May Placement Agent Warrants [Member] 2026 May Placement Agent Warrants This member stands for 2023 Tranche A Preferred Warrants. Two Thousand Twenty Three Tranche A Preferred Warrants [Member] 2023 Tranche A Preferred Warrants 2023 Tranche A warrants This member stands for 2023 Tranche B Preferred Warrants. Two Thousand Twenty Three Tranche B Preferred Warrants [Member] 2023 Tranche B Preferred Warrants 2023 Tranche B warrants Represents information pertaining to 2024 Tranche A warrants. Two Thousand Twenty Four Tranche A Warrants [Member] 2024 Tranche A Warrants Represents information pertaining to 2024 Tranche B warrants. Two Thousand Twenty Four Tranche B Warrants [Member] 2024 Tranche B Warrants Represents information pertaining to 2024 Tranche C warrants. Two Thousand Twenty Four Tranche C Warrants [Member] 2024 Tranche C Warrants Represents information pertaining to 2025 representative warrants. Two Thousand Twenty Five Representative Warrants [Member] 2025 Representative Warrants Common Class A [Member] Class A Units Common Class B [Member] Class B Unit Represents the information pertaining to Series E-1 preferred stock. Series E-1 Preferred Stock [Member] Series E-1 preferred stock Represents the information pertaining to Series E-3 preferred stock. Series E-3 Preferred Stock [Member] Series E-3 preferred stock Sale of Stock [Axis] Sale of Stock [Domain] Represents information pertaining to public offering. Public Offering [Member] Public offering Represents the member information pertaining to registered direct offering. Registered Direct Offering [Member] Registered direct offering Over-Allotment Option [Member] Over allotment option Represents the information pertaining to September 2023 Private Placement. September 2023 Private Placement [Member] September 2023 Private Placement Private Placement [Member] Private placement This member stands for October 2022 Public Offering and Private Placement. October 2022 Public Offering and Private Placement[Member] October 2022 Public Offering and Private Placement Class of Warrant or Right [Line Items] STOCKHOLDERS' EQUITY Aggregate gross upfront amount of shares reserved for future issuance. Stock, Capital Reserved for Future Issuance, Gross Upfront Additional securities purchase agreement, gross upfront Aggregate net upfront amount of shares reserved for future issuance. Stock, Capital Reserved for Future Issuance, Net Upfront Additional securities purchase agreement, net upfront Proceeds from Issuance or Sale of Equity Gross proceeds from stockholders' equity Represents the number of units issued. Number Of Units Issued Number of units issued Represents number of shares in each unit. Number Of Shares In Unit Number of shares in a unit Represents number of warrant in each unit. Number Of Warrants In Unit Number of warrants in a unit Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Number of shares of common stock per warrant Represents the per unit price of units issued. Price per Unit Price per unit Represents volume weighted average price threshold of the issuer's common stock required to be met before a class of warrants or rights becomes callable. Class of Warrant or Right, Call Trigger, Volume Weighted Average Price Threshold Volume weighted average price The number of consecutive trading days during which the specified market price and/or trading volume conditions must be satisfied before a class of warrants or rights becomes callable. Class of Warrant or Right, Call Trigger, Consecutive Trading Days Requirement Number of consecutive trading days Represents average trading volume, based on the volume weighted average price of the issuer's common stock, required to be achieved over a specified consecutive trading-day period before a class of warrants or rights becomes callable Class of Warrant or Right, Call Trigger, Average Trading Volume Threshold Average trading volume Warrants and Rights Outstanding, Term Warrants term Stockholders' Equity Note, Stock Split, Conversion Ratio Reverse stock split ratio Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants issued to purchase shares Number of common shares issuable upon exercise of outstanding warrants (in shares) Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrants (in dollars per share) Exercise Price (in dollars per share) Preferred Stock, Convertible, Shares Issuable Number of shares issuable upon conversion of preferred stock Preferred Stock, Convertible, Conversion Price Conversion price per share Number of days following the announcement of prescription drug use fee act goal date for review by FDA. Number of Days following the Announcement of Prescription Drug Use Fee Act Goal By FDA Number of days following the announcement of receipt of written approval from FDA of its new drug application. Number of Days following the Announcement of Receipt Of Written Approval, New Drug Application Number of days following the date of the Company's public announcement of its receipt of written approval from the FDA Number of days following the announcement of quarterly gross revenue from sales of iopofosine I 131. Number Of Days Following the Announcement Of Quarterly Gross Revenue From Sales Of Drug Number of days following the announcement of quarterly gross revenue from sales of iopofosine I 131. Threshold amount of quarterly gross revenues trigger for expiry of warrants. Threshold Quarterly Gross Revenues Trigger, For Warrant Expiry Date Threshold amount of quarterly gross revenues trigger for expiry of warrants Stock Issued During Period, Shares, New Issues Shares issued Class of Warrant or Right, Outstanding Warrants outstanding Proceeds from Warrant Exercises Proceeds from exercise of warrants Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Settlement of warrants to equity Warrants issued to purchase of common stock. Warrants Issued to Purchase of Common Stock Warrants issued Number of shares issued at exercise of warrants into common shares. Exercise of Warrants Into Common Shares, Shares Exercise of warrants into common shares (in shares) Price of each class of warrant or right. Class of Warrant or Right, Price Per Warrant or Right Price per warrant Number of new warrants issued in exchange of each warrant exercised. Number Of Warrants Issued Number of warrants issued Price paid per share or per unit of warrant or right. Class of Warrant or Right, Price Paid Per Warrant or Right Price paid per warrant The cash inflow from issuance and exercise of warrants during the period. Proceeds From Issuance And Exercise Of Warrants Proceeds from issuance and exercise of warrants Represents information pertaining to 2026 May Pre-Funded Warrants. Two Thousand Twenty Six May Pre-Funded Warrants [Member] 2026 May Pre-Funded Warrants Represents information pertaining to 2026 May Tranche A Common Warrants. Two Thousand Twenty Six May Tranche A Common Warrants [Member] 2026 May Tranche A Common Warrants Represents information pertaining to 2026 May Tranche B Common Warrants. Two Thousand Twenty Six May Tranche B Common Warrants [Member] 2026 May Tranche B Common Warrants Represents information pertaining to 2025 October series I common warrants. Two Thousand Twenty Five October Series One Common Warrants [Member] 2025 October Series I Common Warrants Represents information pertaining to 2025 October series II common warrants. Two Thousand Twenty Five October Series Two Common Warrants [Member] 2025 October Series II Common Warrants Represents information pertaining to 2025 July common warrants. Two Thousand Twenty Five July Common Warrants [Member] 2025 July Common Warrants Expiry date of warrants held. Warrants Expiration Date Expiration Date Measurement Input Type [Axis] Measurement Input Type [Domain] Dividend Dividend Represents information pertaining to October 2022 warrants. October 2022 Warrants [Member] October 2022 Warrants Warrants and Rights Outstanding, Measurement Input Warrants Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 1 [Member] Level 1 Fair Value, Inputs, Level 3 [Member] Level 3 Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Recurring basis Volatility Volatility Risk-free interest rate Risk-free interest rate Expected life (years) Expected life (years) Warrants [Member] Warrants Warrants Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Changes in the fair market value of the warrants Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Ending warrant fair value Beginning warrant fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Change in warrant fair value Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] No definition available. Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table] Option Indexed to Issuer's Equity, Type [Axis] Option Indexed to Issuer's Equity, Type [Domain] This member stands for employee and director stock option. Employee And Director Stock Option Grants [Member] Employee and director stock option grants Location, Statement of Income, Balance [Axis] No definition available. Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items] Employee and director stock option and stock grants: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] This member stands for preferred shares as convertible into common stock. Preferred Shares As Convertible Into Common Stock [Member] Preferred shares on an as-converted-into-common-stock basis Stock Option Activity [Member] Stock options Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] NET LOSS PER SHARE Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Total potentially dilutive shares Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Leases Area of Real Estate Property Area of leased space Security Deposit Security deposit paid Aggregate amount of operating lease payments due over the term of the lease. Lessee, Operating Lease, Aggregate Lease Payments Due Aggregate rent due over term of amended lease Aggregate amount of operating lease payments due over the term of the lease adjusted for certain rent abatements. Lessee, Operating Lease, Aggregate Lease Payments Due, Adjusted For Rent Abatements Aggregate rent, adjusted for certain rent abatements, due over term of amended lease The amount of monthly lease payment due under the terms of the lease agreement. Operating Lease, Monthly Payment Due Monthly rent payment The percentage increase applied to rent payments due on an annual basis per the terms of the lease agreement. Operating Lease, Annual Rent Escalation, Percent Annual percentage increase in rent due Operating Lease, Weighted Average Discount Rate, Percent Reasonable incremental borrowing rate (in percentage) Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year Remaining period of 2026 Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months 2027 Lessee, Operating Lease, Liability, Payments, Due Year Two 2028 Lessee, Operating Lease, Liability, Payments, Due Year Three 2029 Lessee, Operating Lease, Liability, Payments, Due Year Four 2030 Amount of lessee's undiscounted obligation for lease payment for operating lease due after four fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Lessee, Operating Lease, Liability, Payments, Due after Year Four Thereafter Lessee, Operating Lease, Liability, Payments, Due Total undiscounted lease payments Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: Imputed interest Operating Lease, Liability Present value of lease liabilities Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Segments [Axis] Segments [Domain] Represents the information pertaining to single reportable segment. Single Reportable Segment [Member] Single reportable segment Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] SEGMENT INFORMATION Number of Operating Segments Number of operating segments Segment Reporting Information, Profit (Loss) [Abstract] Financial data for the reportable segment Research and Development Expense [Abstract] Research and development: Research and development expense during the period related to the direct costs of Phase 2 study in CLOVER-WaM. Research and Development, Direct Expense, Phase 2 Study in CLOVER-WaM Phase 2 study in WM Research and development expense during the period related to the direct costs of Phase 1 study in pediatric tumors. Research and Development, Direct Expense, Phase 1 Study in Pediatric Tumors Phase 1 study in pediatric tumors Research and development expense during the period related to the direct costs of Phase 1 study in triple negative breast cancer. Research And Development Direct Expense Phase 1 Study In Triple Negative Breast Cancer Phase 1 study in triple-negative breast cancer Research and development expense during the period related to the direct costs of Phase 3 study in CLOVER-WaM. Research and Development, Direct Expense, Phase 3 Study in CLOVER-WaM Phase 3 study in WM Research and development expense during the period related to the direct costs of manufacturing and related costs. Research and Development, Direct Expense, Manufacturing and Related Costs Manufacturing and related costs Research and development expense during the period related to the indirect pre-clinical projects costs. Research and Development, Indirect Expense, Pre-clinical Projects Costs Pre-clinical projects cost Research and development expense during the period related to the indirect general research and development costs . Research and Development, Indirect Expense, General Research and Development Costs General research and development costs The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. General and administrative expenses General and administrative Segment Reporting, Other Segment Item, Amount Other segment items Segment Reporting, Other Segment Item, Composition, Description Other segment items, description